ArticleApplied biochemistry and biotechnology2026
PPARA-Engineered HUCMSC Exosomes Attenuate Sepsis-associated Acute Kidney Injury Via TXNRD1/NRF2 Signaling Activation.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is a life-threatening complication with limited therapeutic options. While both human umbilical cord mesenchymal stem cell-derived exosomes (HUCMSC-exo) and peroxisome proliferator-activated receptor α (PPARα) activation have shown potential in mitigating kidney injury, their functional interplay and underlying mechanisms, particularly concerning ferroptosis, remain unexplored. Exosomes from HUCMSCs were characterized using flow cytometry, transmission electron microscopy (TEM) and western blot. An in vitro SA-AKI model was established using lipopolysaccharide (LPS)-treated HK-2 cells. CCK-8 assay and flow cytometry were utilized to analyze cell viability and apoptosis. Inflammatory cytokine levels were measured by ELISA, and ferroptosis-related indicators were detected by corresponding kits. Bioinformatics analysis, co-immunoprecipitation, and chromatin immunoprecipitation (ChIP) assays were employed to identify and validate the interaction between PPARA and thioredoxin reductase 1 (TXNRD1). A murine model of SA-AKI was used for in vivo validation, with kidney injury evaluated histologically. Typical characteristics of HUCMSCs exo and the positive markers of HUCMSC-ex were identified. Then, it was found that HUCMSCs exo inhibited LPS-induced cell injury and ferroptosis, while PPARA-overexpressing HUCMSCs secreted exosomes that exhibited the same effect. Mechanistically, PPARA was found to directly bind to the promoter of and transcriptionally upregulate TXNRD1. Silencing TXNRD1 abolished the protective effects of PPARA-modified HUCMSC-exo and concurrently suppressed the activation of the downstream Nuclear Factor Erythroid 2-Related Factor 2 (NRF2)/Heme Oxygenase-1 (HO-1) pathway. In vivo, PPARA-exo treatment most effectively ameliorated renal histopathological damage and dysfunction in SA-AKI mice. PPARA fortifies the therapeutic potential of HUCMSC-exo against SA-AKI, at least in part, by direct transcriptional activation of TXNRD1, which subsequently potentiates the NRF2/HO-1 antioxidant signaling pathway to counteract ferroptosis.
Indexed as
Identifiers
41843009What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.